Cozart Bioscience Limited has developed novel lateral flow technology that allows the detection of drugs of abuse in biological fluids and suspect powders. This paper describes the application of this technology for the detection of 3,4-methylenedioxymethamphetamine (MDMA) in oral fluid. Samples (N = 370) were obtained from the analytical laboratory at Cozart Bioscience Limited following their routine analysis for drugs of abuse. Oral fluid samples were screened for the presence of MDMA and methamphetamine using the Cozart | RapiScan System (CRS) and then confirmed for the presence of amphetamines (amphetamine, methamphetamine, MDA, MDMA, MDEA, and MBDB) by gas chromatography-mass spectrometry (GC-MS). In addition to the detection of MDMA and methamphetamine, the CRS cross-reacts with high levels of amphetamine to give a positive result. One hundred and twenty-one samples screened positive using the CRS. Six of these samples were confirmed negative for MDMA and methamphetamine, but contained very high levels of amphetamine. Employing a screening cutoff of 45 ng/mL for the CRS and a confirmation cutoff of 30 ng/mL for GC-MS, the sensitivity, specificity, and accuracy were 96.6, 96.8, and 96.8%, respectively. When applying the Substance Abuse and Mental Health Services Administration recommended confirmation cutoff for amphetamines of 50 ng/mL, the sensitivity, specificity, and accuracy increased marginally to 98.3, 96.9, and 97.3%, respectively.
Introduction
One of the biggest problems facing today's society is the use and misuse of drugs (1) . Psychoactive drugs in particular are of great concern as many cases of violent crime may be a direct result of misusing these drugs (2) .
Amphetamine, methamphetamine, and designer drugs, such as 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxyphenyl-2-butanamine (MBDB), and 3,4-methylenedioxy-Noethylamphetamine (MDEA), are central nervous stimulants that are abused for their psychotropic effects including euphoria and increased energy and alertness.
Driving under the influence of drugs or alcohol is responsible for thousands of accidents every year and up to 25% of accidents involve drivers who tested positive for drugs (3) . In a roadside study in Belgium, blood analysis of drivers suspected of impairment revealed the presence of MDMA in 35% of cases. Amphetamine, cocaine, and cannabis were also detected in many of these cases (4) .
The use of oral fluid as a matrix for drug monitoring in treatment, workplace, criminal justice, and driving under the influence testing programs is becoming increasingly popular (5, 6) . Oral fluid can provide a readily available, non-invasive medium, without the intrusion of privacy, which occurs with the observed collection of a urine sample. It is believed that levels of drugs measured in oral fluid may parallel the levels in blood, therefore making oral fluid an alternative analytical specimen to blood for roadside testing (7) .
A number of on-site testing devices for drugs of abuse in oral fluid exist (8) (9) (10) (11) . The advantages of on-site testing are rapid turn around times, reduced costs, and the fact that the test can be carried out virtually anywhere (12) .
The Cozart RapiScan System (CRS) is an example of lateral flow technology, which is also marketed as the Drug Detection System (DDS), and it is a fully integrated qualitative screening device designed for the on-site detection of drugs of abuse in oral fluid (13, 14) . The device has been used successfully for monitoring compliance within treatment centers, criminal justice settings, and more recently at the roadside (15) (16) (17) .
This study investigates the ability of the CRS to correctly detect the presence of MDMA and methamphetamine in oral fluid specimens to establish drug use.
from Cerilliant (LGC Promochem, Teddington, U.K.). The derivatizing reagent pentafluoropropionic anhydride (PFPA) was purchased from Sigma Aldrich (Dorset, U.K.). Solid-phase extraction (SPE) cartridges, Bond Elut TM Certify (50 rag, 3 mL), were purchased from Varian (Surrey, U.K.). All other reagents and solvents were of analytical grade and were purchased from VWR International (Leicestershire, U.K.). The CRS, drug test cartridges, and oral fluid collectors were supplied by Cozart Bioscience (Abingdon, Oxfordshire, U.K.).
Methods

Specimens
Three hundred and seventy oral fluid specimens were obtained from the analytical laboratory at Cozart Bioscience following their routine analysis for drugs of abuse. Prior to submission to the laboratory 1 mL of oral fluid was collected from each individual using the CRS. The oral fluid soaked sample pad was then inserted into the transport tube, which contained 2 mL of Cozart proprietary buffer. This collection method resulted in a 1:3 dilution of the sample, and all concentrations noted are corrected for neat oral fluid. Detailed information regarding the individuals was not available. The time delay between receipt of samples into the laboratory for routine screening and their screening using the CRS was less than 4 months, during which time the samples were stored at -20~
Screening
Samples were screened using the CRS methamphetamine/ MDMA test cartridge according to the manufacturer protocol (18) . In brief, four drops of oral fluid/buffer mixture were added to the cartridge using a disposable Pasteur pipette. As soon as the fluid appeared in the cartridge window, the cartridge was inserted into the CRS instrument and the timer was initiated by pressing the start button. Following a 5-rain incubation, the cartridge was read and the result interpreted by the RapiScan instrument, which then displayed either positive or negative on the screen, and a printout of the results was produced from the attached printer. Following screening, the remaining oral fluid was stored frozen at -20~ until analysis by GC-MS.
The CRS methamphetamine/MDMA test cartridge has a set cutoff of 45 ng/mL in neat oral fluid. The manufacturer states that other designer amphetamines (such as MBDB and MDEA) show cross-reactivity with the assay, and that concentrations of amphetamine greater than 30 pg/mL will give a positive screen result (18) . Details of the product cross-reactivity can be seen in Tables I and II .
Sample Preparation and GC-MS Analysis
Specimens were analyzed for amphetamine, methamphetamine, MDA, MDMA, MDEA, and MBDB according to a previously published procedure (19) . Specimens were allowed to equilibrate to room temperature and mixed, and 500 pL was taken for analysis. Deuterated internal standards amphet- 288  289  290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335 amine-d11, methamphetamine-du, MDA-ds, MDMA-ds, MDEAd6, and MBDB-d5 (1 ~g/mL stock solutions) were added to each sample and standard, followed by 1 mL of 0.]M phosphate buffer (pH 7.4).
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SPE
The amphetamines were extracted by SPE using Bond Elut Certify (50 rag, 3 mL). The columns were conditioned with 1 mL of methanol, followed by 1 mL of phosphate buffer (pH 7.4, 0.1M). The sample was loaded onto the column and then washed with 1 mL of deionized water. The column pH was adjusted with 0.5 mL acetic acid (pH 3.3, 0.01M) and dried on a full vacuum for 10 min. The column was then washed with a further 50 IJL of methanol and dried on a full vacuum for 1 rain.
Three milliliters of acetone/chloroform (1:1) was added as the final wash step. The amphetamines were then eluted with i mL ethylacetate containing 2% NH4OH (98:2, v/v). Tartaric acid (100 ~L) (1 mg/mL in ethylacetate) was added to the eluates and evaporated to dryness at room temperature under nitrogen. The samples were then reconstituted with 100 I~L PFPA/EtOAc (1:1) and again evaporated to dryness at room temperature under nitrogen. The samples were then reconstituted in 100 lJL of ethylacetate.
GC-MS Parameters
The GC-MS was an Agilent 5973N with 6890 GC run in electron impact mode with splitless injection and equipped with Rtx-5Sil MS (30 m x 0.25-ram i.d, 0.25 IJm) capillary column. The injector port temperature was set at 290~ The temperature program consisted of an initial 2 rain at 55~ that was ramped at 20~ to 200~ then ramped to 250~ at 10~
and finally to 300~ at 25~ and held for 2 rain. The mass-selective detector was operated in the selectedion monitoring mode. Three ions for all analytes and their internal standards were monitored and are listed in Table III .
Sensitivity, specificity, and accuracy
Sensitivity is the true positive rate and was calculated from the tally of true positives (TP) and false negatives (FN): Sensitivity --TP/(TP + FN) x 100%. Specificity was calculated from the tally of false positives (FP) and true negatives (TN): Specificity = TN/(TN +FP) x 100%. Overall accuracy was calculated as Accuracy = (TP + TN)/(TP + FP +TN + FN) x 100%.
GC-MS method validation data
The GC-MS method for amphetamines in oral fluid was validated for the purpose of ISO17025 accreditation and the findings were published as an internal report (20) . The findings showed the method linearity to be greater than 0.9928 for all amphetamines quantified using seven data points ranging from 0 to 180 ng/mL. Inter-and intra-assay precision were found to be less than 11% and less than 4%, respectively. The limits of detection (LOD) for amphetamine, methamphetamine, MDA, MDMA, MDEA, and MBDB were 2, 1, 5, 1, 2, and 1 ng/mL, respectively, with the limits of quantitation (LOQ) as 5 ng/mL for all compounds excluding methamphetamine, which was 2 ng/mL.
Results
In all, 121 oral fluid specimens screened positive using the CRS for the detection of methamphetamine and MDMA, and 230 specimens were confirmed by GC-MS to contain amphetamines above the LOQ of the assay (see Table IV Six samples screened positive by the CRS, but did not contain detectable quantities of MDMA or methamphetamine by GC-MS. These samples contained levels of amphetamine, which were much greater than the top calibration standard of 180 ng/mL. Two-hundred, forty-nine samples screened negative by the CRS with its 45 ng/mL cutoff: 245 of these samples were confirmed negative using a GC-MS cutoff of 30 ng/mL, and 247 were confirmed negative using the Substance Abuse and Mental Health Services Administration (SAMSHA) cutoff of 50 ng/mL (see Table V ). The four discrepant samples contained MDMA levels of 44, 47, 53, and 54 ng/mL.
The numbers of TP, FN, FP, and TN were determined by comparing the CRS test results to the gold standard method GC-MS using a cutoff of 30 ng/mL and the SAMSHA recommended cutoff of 50 ng/mL of amphetamines in oral fluid (see Table V ).
The sensitivity, specificity, and accuracy of the CRS for the detection of MDMA and methamphetamine at a CRS cutoff of 45 ng/mL in neat oral fluid versus a GC-MS cutoff of 30 ng/mL were 96.6, 96.8, and 96.8%, respectively. When the SAMSHA recommended cutoff of 50 ng/mL was used, these values increased slightly to 98.3, 96.9, and 97.3%.
Conclusions
MDMA and methamphetamine were identified in 34.9% (N = 129) and 0.8% (N = 3), respectively, of the samples tested. Amphetamine was present either alone or in combination with other amphetamines in 144 cases, and six of the samples that screened positive using the CRS contained amphetamine only. The manufacturer protocol states a positive response will be obtained with d-amphetamine levels of 30 IJg/mL and above; therefore, it is suggested that these six samples contained levels at or in excess of this concentration. Serial dilutions of these samples were not possible because of there being insufficient sample for further analysis. One sample, which gave a positive response using the CRS, was later found to contain a very high concentration of pseudoephedrine. It is suggested that the level of pseudoephedrine in this sample may have also exceeded the 30 lJg/mL level, which triggers a positive response according to the manufacturer protocol.
Though the manufacturer has carried out extensive cross-reactivity studies, the list is not exhaustive and there may be other amphetamines and their derivatives that will also crossreact to produce a positive response with the CRS. This is an area where further studies can be carried out to assess the full extent of the cross-reactivity, with the identification of these compounds by GC-MS in samples collected from known drug users.
When applying the GC-MS cutoff of 30 ng/mL, there were a total of four false negatives, this number decreased to two false negatives when the SAMSHA cutoff of 50 ng/mL was applied. The levels of MDSe. in these four samples were between 44 and 54 ng/mL, which is within 20% of the RapiScan cutoff of 45 ng/mL.
The CRS for MDMA and methamphetamine in oral fluid demonstrated excellent sensitivity and specificity with an overall accuracy of 96.8% when compared with GC-MS at a cutoff of 30 ng/mL. The overall accuracy increased slightly to 97.3% when the SAMSHA recommended cutoff of 50 ng/mL was applied.
As a screening tool for the identification of MDMA in oral fluid the CRS performs very well and would be a suitable device in many situations, including the workplace or at the roadside.
The sample population in this study showed a high number of MDMA positives and a lack of samples containing methamphetamine; however, this is consistent with the reported use of amphetamines in the U.K. Future work will include testing populations of samples containing methamphetamine, as well as the assessment of quantitative concentrations of MDMA and methamphetamine in oral fluid samples versus self-report data.
